Tasmina Goraya

Tasmina is a partner in the firm's Patent team and is a core member of the firm's UK and International Life Sciences Group.

She works with our clients in the life sciences sector advising on contentious and non-contentious areas, including a broad range of regulatory and compliance issues relating to pharmaceuticals, medical devices, food supplements, human cells and tissue. Tasmina regularly advises on patent, regulatory and contract disputes, with a particular focus on arbitrations as well as the regulatory aspects of corporate transactions. Tasmina further assists clients with specialist agreements, such as clinical trials agreements.

CV

Since 2019 Partner, Taylor Wessing

2017 - 2019 Senior Associate, Taylor Wessing

2016 - 2017 Associate, Taylor Wessing

职业发展

Since 2019 Partner, Taylor Wessing

2017 - 2019 Senior Associate, Taylor Wessing

2016 - 2017 Associate, Taylor Wessing

教育

2013 Postgraduate Diploma, Intellectual Property Law and Practice, Oxford University

2011 Admitted as a solicitor, England & Wales

2009 Legal Practice Course, College of Law

语言

奖励

Legal 500 UK 2025

Featured

Legal 500 UK 2025

Chambers and Partners UK 2024

Legal 500 UK 2022

Experience

Sale of S&IP business

Halyard Health on the sale of its surgical and infection prevention (S&IP) business to OMI.

Tasmina Goraya, PhD

Evelyne Friedel

Christian Dekoninck

Apotex's EUR74m sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Colin McCall

Simon Cohen

Tasmina Goraya, PhD

Jason Rawkins

Simon Jupp

Bart Hunnekens

Roos Seesing

Acting on a multi-million pound arbitration claim

A medical research organisation in a multi-million pound arbitration claim against a Japanese pharmaceutical company, seeking royalties due on the sales of a blockbuster drug resulting from an R&D collaboration between the parties.

Chris Thornham

Tasmina Goraya, PhD

Gemma Broughall